Sathe, N. et al. Pseudomonas aeruginosa: Infections and novel approaches to treatment knowing the enemy the threat of Pseudomonas aeruginosa and exploring novel approaches to treatment. Infect. Med. 2 (3), 178–194 (2023).
Mendes, O. R. Chap. 48 – The challenge of pulmonary Pseudomonas aeruginosa infection: How to bridge research and clinical pathology. In Viral, Parasitic, Bacterial, and Fungal Infections, Bagchi, D.; Das, A.; Downs, B. W., Eds. Academic Press: ; pp 591–608. (2023).
Drenkard, E. Antimicrobial resistance of Pseudomonas aeruginosa biofilms. Microbes Infect. 5 (13), 1213–1219 (2003).
WHO Bacterial Priority. Pathogens List, 2024.
WHO publishes list of bacteria for which new antibiotics are urgently needed. (2017).
Dedrick, R. M. et al. Potent antibody-mediated neutralization limits bacteriophage treatment of a pulmonary Mycobacterium abscessus infection. Nat. Med. 27 (8), 1357–1361 (2021).
Leitner, L. et al. Intravesical bacteriophages for treating urinary tract infections in patients undergoing transurethral resection of the prostate: A randomised, placebo-controlled, double-blind clinical trial. Lancet Infect. Dis. 21 (3), 427–436 (2021).
Tan, X. et al. Clinical experience of personalized phage therapy against carbapenem-resistant acinetobacter baumannii lung infection in a patient with chronic obstructive pulmonary disease. Front. Cell. Infect. Microbiol. 11, 631585 (2021).
Liu, D. et al. The safety and toxicity of phage therapy: A review of animal and clinical studies. Viruses 13 (2021). (7).
Chegini, Z. et al. Bacteriophage therapy against Pseudomonas aeruginosa biofilms: A review. Ann Clin Microbiol Antimicrob 19 (1), 45. (2020).
Tabassum, R. et al. Complete genome analysis of a siphoviridae phage TSK1 showing biofilm removal potential against Klebsiella pneumoniae. Sci. Rep. 8 (1), 17904 (2018).
Gordillo Altamirano, F. L. & Barr, J. J. Phage Therapy in the Postantibiotic Era. Clin Microbiol Rev 32 (2). (2019).
Fortier, L. C. & Sekulovic, O. Importance of prophages to evolution and virulence of bacterial pathogens. Virulence 4 (5), 354 – 65 (2013).
Schroven, K., Aertsen, A. & Lavigne, R. Bacteriophages as drivers of bacterial virulence and their potential for biotechnological exploitation. FEMS Microbiol. Rev. 45 (1), fuaa041 (2021).
Schooley, R. T. et al. Development and use of personalized Bacteriophage-Based therapeutic cocktails to treat a patient with a disseminated resistant acinetobacter baumannii infection. Antimicrob Agents Chemother 61 (2017). (10).
LaVergne, S. et al. Phage therapy for a Multidrug-Resistant acinetobacter baumannii craniectomy site infection. Open Forum Infect. Dis 5 (4), (2018).
Ferry, T. et al. Personalized bacteriophage therapy to treat pandrug-resistant spinal Pseudomonas aeruginosa infection. Nature Communications 13 (1), 4239 (2022).
Köhler, T. et al. Personalized aerosolised bacteriophage treatment of a chronic lung infection due to multidrug-resistant Pseudomonas aeruginosa. Nature Communications 14 (1), 3629 (2023).
Overhage, J., Schemionek, M., Webb, J. S. & Rehm, B. H. Expression of the psl operon in Pseudomonas aeruginosa PAO1 biofilms: PslA performs an essential function in biofilm formation. Appl Environ Microbiol 71 (8), 4407-13 (2005).
Chan, B. K. et al. Phage selection restores antibiotic sensitivity in MDR Pseudomonas aeruginosa. Sci. Rep. 6, 26717 (2016).
León, M. & Bastías, R. Virulence reduction in bacteriophage resistant bacteria. Front. Microbiol. 6, 343 (2015).
Balasubramanian, D., Kumari, H. & Mathee, K. Pseudomonas aeruginosa ampr: An acute-chronic switch regulator. Pathog Dis. 73 (2), 1–14 (2015).
Glen, K. A. & Lamont, I. L. β-lactam resistance in Pseudomonas aeruginosa: Current status, future prospects. Pathogens 10 (2021).
Cabot, G. et al. Genetic Markers of Widespread Extensively Drug-Resistant Pseudomonas aeruginosa High-Risk Clones. 56, 6349–6357 (2012).
Tsutsumi, Y., Tomita, H. & Tanimoto, K. Identification of novel genes responsible for overexpression of ampc in Pseudomonas aeruginosa PAO1. 57 (12), 5987–5993 (2013).
Sada, M. et al. Molecular evolution of the Pseudomonas aeruginosa DNA gyrase GyrA gene. Microorganisms 10 (2022).
Braz, V. S., Furlan, J. P. R., Fernandes, A. F. T. & Stehling, E. G. J. F. m. l., Mutations in NalC induce MexAB-OprM overexpression resulting in high level of aztreonam resistance in environmental isolates of Pseudomonas aeruginosa. 363 16 (2016).
Nmema, E. E., Osuagwu, C. S., Anaele, E. N. J. & Research, M. J. o. A. i. M.; oprD Genes Detected in Pseudomonas aeruginosa Isolates from a Teaching Hospital but Lost in a carbapenem-resistant Strain. 2019.
Dößelmann, B. et al. Rapid and consistent evolution of colistin resistance in extensively Drug-Resistant Pseudomonas aeruginosa during morbidostat culture. Antimicrob Agents Chemother 61 (2017).
Craig, L., Forest, K. T. & Maier, B. Type IV pili: Dynamics, biophysics and functional consequences. Nat. Rev. Microbiol. 17 (7), 429–440 (2019).
García-Cruz, J. C. et al. Resistance against two lytic phage variants attenuates virulence and antibiotic resistance in Pseudomonas aeruginosa. Front Cell. Infect. Microbiol 13, (2023).
Veeranagouda, Y. et al. Ssg, a putative glycosyltransferase, functions in lipo- and exopolysaccharide biosynthesis and cell surface-related properties in Pseudomonas alkylphenolia. FEMS Microbiol. Lett. 315 (1), 38–45 (2011).
Evans, B. A. & Rozen, D. E. A Streptococcus pneumoniae infection model in larvae of the wax moth galleria Mellonella. Eur. J. Clin. Microbiol. Infect. Dis. 31 (10), 2653–2660 (2012).
Kropinski, A. M. & Chadwick, J. S. The pathogenicity of rough strains of Pseudomonas aeruginosa for galleria Mellonella. Can. J. Microbiol. 21 (12), 2084 (1975).
Whitfield, C., Williams, D. M. & Kelly, S. D. Lipopolysaccharide O-antigens-bacterial glycans made to measure. J. Biol. Chem. 295 (31), 10593–10609 (2020).
Martin, P. R., Hobbs, M., Free, P. D., Jeske, Y. & Mattick, J. S. Characterization of pilq, a new gene required for the biogenesis of type 4 fimbriae in Pseudomonas aeruginosa. Mol. Microbiol. 9 (4), 857–868 (1993).
Narulita, E., Addy, H. S., Kawasaki, T., Fujie, M. & Yamada, T. The involvement of the PilQ secretin of type IV pili in phage infection in ralstonia solanacearum. Biochem. Biophys. Res. Commun. 469 (4), 868–872 (2016).
Niazy, A. A., Lambarte, R. N. A. & Alghamdi, H. S. De Novo pyrimidine synthesis pathway Inhibition reduces motility virulence of Pseudomonas aeruginosa despite complementation. J. King Saud Univ. – Sci. 34 (4), 102040 (2022).
Maddocks, S. et al. Bacteriophage therapy of Ventilator-associated pneumonia and empyema caused by Pseudomonas aeruginosa. Am. J. Respir Crit. Care Med. 200 (9), 1179–1181 (2019).
Chen, P. et al. Bacteriophage therapy for empyema caused by carbapenem-resistant Pseudomonas aeruginosa. Biosci. Trends. 16 (2), 158–162 (2022).
Gurney, J., Brown, S. P., Kaltz, O. & Hochberg, M. E. Steering phages to combat bacterial pathogens. Trends Microbiol. 28 (2), 85–94 (2020).
Markwitz, P. et al. Emerging phage resistance in Pseudomonas aeruginosa PAO1 is accompanied by an enhanced heterogeneity and reduced virulence. Viruses 13 (2021).
Castledine, M. et al. Parallel evolution of Pseudomonas aeruginosa phage resistance and virulence loss in response to phage treatment in vivo and in vitro. eLife 11, e73679 (2022).
Chan, B. K. et al. Phage selection restores antibiotic sensitivity in MDR Pseudomonas aeruginosa. Sci Rep 6 (1), 26717 (2016).
Tzeng, C. T., Huang, Y. H. & Huang, C. Y. Crystal structure of dihydropyrimidinase from Pseudomonas aeruginosa PAO1: Insights into the molecular basis of formation of a dimer. Biochem. Biophys. Res. Commun. 478 (3), 1449–1455 (2016).
Olawade, D. B. et al. Phage therapy: A targeted approach to overcoming antibiotic resistance. Microb. Pathog. 197, 107088 (2024).
Eghbalpoor, F., Gorji, M., Alavigeh, M. Z. & Moghadam, M. T. Genetically engineered phages and engineered phage-derived enzymes to destroy biofilms of antibiotics resistance bacteria. Heliyon 10 (15), e35666 (2024).
Köhler, T. et al. Personalized aerosolised bacteriophage treatment of a chronic lung infection due to multidrug-resistant Pseudomonas aeruginosa. Nat Commun 14 (1), 3629 (2023).
Ferry, T. et al. Personalized bacteriophage therapy to treat pandrug-resistant spinal Pseudomonas aeruginosa infection. Nat Commun 13 (1), 4239 (2022).
Abedon, S. T. Phage therapy of pulmonary infections. Bacteriophage 5 (1), e1020260 (2015).
Singer, M. et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA 315 (8), 801–810 (2016).
Knaus, W. A., Draper, E. A., Wagner, D. P. & Zimmerman, J. E. APACHE II: A severity of disease classification system. Crit. Care Med. 13 (10), 818–829 (1985).
Institute, C. a. L. S., Performance Standards for Antimicrobial Susceptibility Testing. 2022.
Chen, L. et al. In vitro design and evaluation of phage cocktails against Aeromonas salmonicida. Front Microbiol 9, 1476 (2018).
Bachrach, U. & Friedmann, A. Practical procedures for the purification of bacterial viruses. Appl. Microbiol. 22 (4), 706–715 (1971).
Lood, C. et al. Genomics of an endemic cystic fibrosis burkholderia multivorans strain reveals low within-patient evolution but high between-patient diversity. PLoS Pathog 17 (3), e1009418 (2021).
Chin, C. S. et al. Nonhybrid, finished microbial genome assemblies from long-read SMRT sequencing data. Nat Methods 10 (6), 563–569 (2013).
Berlin, K. et al. Assembling large genomes with single-molecule sequencing and locality-sensitive hashing. Nat Biotechnol 33 (6), 623–630 (2015).
Seemann, T. Prokka: Rapid prokaryotic genome annotation. Bioinformatics 30 (14), 2068 (2014).
Starikova, E. V. et al. Phigaro: High-throughput prophage sequence annotation. Bioinformatics 36 (12), 3882–3884 (2020).
Bertelli, C. et al. IslandViewer 4: Expanded prediction of genomic Islands for larger-scale datasets. Nucleic Acids Res. 45(W1), W30–W35 (2017).
Tsai, C. J., Loh, J. M. S. & Proft, T. Galleria mellonella infection models for the study of bacterial diseases and for antimicrobial drug testing. Virulence 7(3), 214–229 (2016).
Hill, L., Veli, N. & Coote, P. J. Evaluation of galleria Mellonella larvae for measuring the efficacy and pharmacokinetics of antibiotic therapies against Pseudomonas aeruginosa infection. Int J. Antimicrob. Agents 43 (3), 254 – 61 (2014).
Kim, S. G. et al. Isolation and characterisation of pVa-21, a giant bacteriophage with anti-biofilm potential against Vibrio alginolyticus. Sci Rep 9 (1), 6284 (2019).
Kilmury, S. L. N. & Burrows, L. L. The Pseudomonas aeruginosa PilSR Two-Component System Regulates Both Twitching and Swimming Motilities. mBio 9 (4) (2018).
Hashimoto, S. & Shime, N. Evaluation of semi-quantitative scoring of gram staining or semi-quantitative culture for the diagnosis of ventilator-associated pneumonia: A retrospective comparison with quantitative culture. J. Intensive Care. 1 (1), 2 (2013).
